Details for: POMALYST
Company: CELGENE INC
| DIN | DIN name | Active Ingredient(s) | Strength | Dosage Form | Route of Administration |
|---|---|---|---|---|---|
| 02419580 | POMALYST | POMALIDOMIDE | 1 MG | CAPSULE | ORAL |
| 02419599 | POMALYST | POMALIDOMIDE | 2 MG | CAPSULE | ORAL |
| 02419602 | POMALYST | POMALIDOMIDE | 3 MG | CAPSULE | ORAL |
| 02419610 | POMALYST | POMALIDOMIDE | 4 MG | CAPSULE | ORAL |
Summary Reports
Summary Basis of Decision
Summary Safety Review - Pomalyst (pomalidomide) and Thalomid (thalidomide) - Assessing the potential risk of Progressive Multifocal Leukoencephalopathy
Summary Safety Review - Pomalyst (pomalidomide) and Thalomid (thalidomide) - Assessing the potential risk of Progressive Multifocal Leukoencephalopathy
Consumer Information
The Consumer Information is not yet available in the Drug and Health Product Register. Try searching on the active ingredient(s) to find other similar products.